 Chiasma Inc NASDAQ: CHMA submitted a marketing application to the European Medicines Agency seeking approval of Mycapssa oral octreotide capsules as maintenance therapy for adults with acromegaly. The application is supported by positive results from Phase 3 MPOWERED non-inferiority trial comparing Mycapssa to long-acting injectable somatostatin analogs iSSAs. 